Researcher

Xin Liu

Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · JOURNAL ARTICLE

Dynamic epidemiological changes of hand, foot, and mouth disease and real-world effectiveness of EV-A71 vaccination: A case study in Shanghai (2009-2023).

Human Vaccines & Immunotherapeutics

Rigorous test-negative design study with large real-world population (73,160 cases) over 15 years demonstrating vaccine effectiveness against the target pathogen with precise confidence intervals; not practice-changing because vaccination policy was already implemented.

Strong EvidenceVaccine Efficacy Xin Liu Mei Zeng

Reported

Primary endpoint: VE two-dose aga…89.9%

95% CI for two-dose VE74.5-96.0

VE one-dose against EV-A71-associ…67.9%

MAY 13, 2026 · JOURNAL ARTICLE

Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis.

Renal Failure

Meta-analysis of 3 RCTs and 8 observational studies shows apixaban and rivaroxaban associated with lower bleeding risk versus warfarin in dialysis patients with AF, but efficacy endpoints show substantial heterogeneity and RCT-only analysis lacked statistical significance; evidence is suggestive but requires dedicated large RCTs.

PromisingXiaoyuan Wu Xin Liu Kidney Failure, Chronic

Reported

Major bleeding risk ratio0.57 (95% CI: 0.51–0.63)

Gastrointestinal bleeding risk ra…0.66 (95% CI: 0.57–0.76)

Intracranial hemorrhage risk ratio0.54 (95% CI: 0.36–0.83)